Ad-hoc | 26 February 2013 07:04
Fresenius SE & Co. KGaA / Key word(s): Final Results
26.02.2013 07:04
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Centennial year with record sales and earnings - Group net income exceeds
guidance - Positive outlook for 2013
Group sales* increased by 18% (13% in constant currency) to EUR19,290
million (2011: EUR16,361 million). Organic sales growth was 6%.
Acquisitions contributed a further 8%. Divestitures reduced sales growth by
1%. Currency translation had a positive effect of 5%.
Group EBIT** increased by 20% (14% in constant currency) to EUR3,075
million (2011: EUR2,563 million). EBIT margin improved by 20 basis points
to 15.9% (2011: 15.7%).
Group net income*** increased by 22% (17% in constant currency) to EUR938
million (2011: EUR770 million). Earnings per share increased by 15% to
EUR5.42 (2011: EUR4.73).
Including special items, Group net income attributable to Fresenius SE &
Co. KGaA reached EUR926 million or EUR5.35 per share.
Based on the excellent financial results, the Management Board will propose
to the Supervisory Board a dividend increase of 16% to EUR1.10 per ordinary
share (2011: EUR0.95). The 16% increase reflects our new dividend policy,
which aligns dividend with earnings per share growth (before special items)
and broadly maintains a pay-out ratio of 20% to 25%.
For 2013, Fresenius projects Group sales growth of 7% to 10% in constant
currency. Group net income**** is expected to increase by 7% to 12% in
constant currency.
The Group's U.S. GAAP financial results as of December 31, 2012 are
adjusted for a non-taxable investment gain and other one-time costs at
Fresenius Medical Care and for one-time costs related to the offer to
RHÖN-KLINIKUM AG shareholders. Adjusted earnings represent the Group's
business operations in the reporting period.
* 2011 sales were adjusted according to a U.S. GAAP accounting change. The
sales adjustment of -EUR161 million solely relates to Fresenius Medical
Care North America.
** 2012 adjusted for one-time costs of EUR6 million (non-financing
expenses) related to the offer to RHÖN-KLINIKUM AG shareholders and other
one-time costs of EUR86 million at Fresenius Medical Care.
*** Net income attributable to shareholders of Fresenius SE & Co. KGaA -
adjusted for a non-taxable investment gain of EUR34 million and other
one-time costs of EUR17 million at Fresenius Medical Care and for one-time
costs of EUR29 million related to the offer to the shareholders of
RHÖN-KLINIKUM AG. 2011 adjusted for the effects of mark-to-market
accounting of the Mandatory Exchangeable Bonds and the Contingent Value
Rights.
**** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2013 adjusted for one-time integration costs of Fenwal, Inc. (~EUR 50
million pre tax); 2012 adjusted for a non-taxable investment gain and other
one-time costs at Fresenius Medical Care as well as for one-time costs
related to the offer to RHÖN-KLINIKUM AG shareholders.
(Financial statements according to U.S. GAAP)
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management
Bad Homburg v.d.H., February 26, 2013
End of note
26.02.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
Terminbörse EUREX
End of Announcement DGAP News-Service
---------------------------------------------------------------------------